Study guide
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models
Key Takeaways Explain This Topic AI
Quantal data are all-or-none incidences (death, tumor, malformation); continuous data are graded measurements (body weight, ALT). LD50, LC50, ED50, and EC50 are midpoint potencies, not chronic points of departure.
A frequency plot of individual thresholds is often roughly bell-shaped; the cumulative plot is the sigmoid whose 50% point is the LD50 or ED50. Slope, plateau (Emax), and midpoint are separate geometric properties.
Most noncancer apical effects are treated as threshold (nonlinear) processes. EPA 2005 cancer guidelines use default linear no-threshold extrapolation for agents with a mutagenic mode of action.
Hormesis is a J-shaped or inverted-U low-dose stimulation with high-dose inhibition; endocrine non-monotonic curves change slope sign with dose. Neither pattern is an automatic default for chemical reference values.
Therapeutic index is TD50/ED50 (example: 200/20 = 10). Essential nutrients follow a U-shape (deficiency plus excess). PBPK models replace administered mg/kg with internal metrics such as AUC, Cmax, or amount metabolized.
Last updated: September 2026
Why dose–response is Domain III.C
Handbook III.C.1 asks whether you can describe how a biological system changes as dose or concentration changes, then defend a model shape for that endpoint and mode of action . Independent ExamFinch teaching in this section covers quantal versus continuous data, potency midpoints ( LD50 , LC50 , ED50 , EC50 ), curve geometry ( slope , plateau , midpoint ), frequency versus cumulative plots, hormesis and other non-monotonic shapes, the usual threshold treatment of most noncancer effects, the U.S. Environmental Protection Agency (EPA) 2005 Guidelines for Carcinogen Risk Assessment default linear no-threshold (LNT) treatment of mutagenic carcinogens, the therapeutic index , the U-shaped curve for essential nutrients , and why physiologically based pharmacokinetic (PBPK) models replace administered dose with an internal metric. This material is not an ABT product and does not claim official approval, review, or partnership with ABT or EPA.
Domain III.C is 9% of the examination. Items here punish mixing an acute lethality screen with a chronic cancer assessment, or treating every sigmoid as proof that a biological threshold equals the study NOAEL.
Quantal versus continuous responses
Quantal (dichotomous) data are all-or-none for each animal or person: dead or alive, tumor present or absent, malformation yes or no. The group response is an incidence (3/10, 30%). Likelihood is binomial. Extra risk and added risk live on this scale (section 12.2).
Continuous data are graded measurements: terminal body weight, serum alanine aminotransferase ( ALT ), red-cell acetylcholinesterase activity, fetal weight. Each animal contributes a number. Modeling uses means and variances. A common benchmark is a change of one control standard deviation (1 SD) , not a 10% incidence.
The same study can contain both: hepatocellular necrosis scored present/absent (quantal) and ALT in U/L (continuous). Do not convert a mean 12% ALT rise into an “LD12.” Do not treat a 50% drop in a continuous enzyme activity as an LD50 unless death was the endpoint.
LD50, LC50, ED50, EC50
These are midpoint potency numbers. They locate the curve on the dose axis. They are not safety limits, not chronic points of departure, and not first-in-human starting doses.
Symbol Quantity Typical setting What 50% means
LD50 Median lethal dose Acute oral, dermal, or injection lethality Dose estimated to kill 50% of the tested animals (quantal death)
LC50 Median lethal concentration Acute inhalation; aquatic lethality Air or water concentration killing 50%
ED50 Median effective dose Pharmacology; some toxicology Dose producing 50% of Emax , or affecting 50% of subjects, depending on how the endpoint was defined
EC50 Median effective concentration In vitro assays; aquatic sublethal tests Concentration at the midpoint of a concentration–response curve
Worked midpoint. Ten rats per group receive a single oral gavage. Deaths: 0/10 at 50 mg/kg , 2/10 at 100 , 5/10 at 200 , 8/10 at 400 , 10/10 at 800 . Incidence crosses 50% at 200 mg/kg , so the LD50 is near 200 mg/kg . That number does not tell you the NOAEL of a 90-day study, the BMDL10 of a cancer bioassay, or a therapeutic starting dose. It only locates acute lethality.
Slope, plateau, and midpoint
A sigmoid (logistic, probit, Hill) has three geometric jobs that items like to separate:
Midpoint — LD50/ED50/EC50: where the curve is located on the x-axis.
Plateau (Emax) — the maximum response. Quantal incidence cannot exceed 100% . Continuous inhibition may plateau below 100% if residual activity remains.
Slope (Hill coefficient n ) — how fast the curve rises between about 20% and 80% of Emax. A steep slope means a small dose increment moves the population from few responders to most responders (some ion-channel toxins, some acute lethality curves). A shallow slope means effects accumulate over a wide dose range (many chronic organ-weight changes).
Teaching form of the Hill equation:
E = Emax × C^n / (EC50^n + C^n)
If n = 1 , the rise is gradual. If n = 4 , the curve is almost a step. Two chemicals can share an ED50 of 10 mg/kg and still differ enormously in how dangerous a two-fold dosing error is—that difference is slope , not the midpoint.
Linear versus nonlinear in risk-assessment language is about the low-dose region, not about whether a laboratory sigmoid looks curved on arithmetic paper. A probit fit to log-dose is a nonlinear function of dose and still becomes a straight line through the origin in an EPA mutagenic-cancer extrapolation below the PoD. A Michaelis–Menten metabolic saturation is nonlinear and can produce a threshold-like apical effect once repair is exceeded. Name the region and the endpoint before you name the model.
Common families, conceptually (not a software tutorial): probit (cumulative normal of log dose), logit (log-odds linear in log dose), multistage polynomials used historically in cancer assessment, Weibull , and for continuous data power , Hill , and exponential models. Model shopping is section 12.2; this section is shape literacy.
Frequency versus cumulative curves
Individual animals do not all share one threshold. A frequency plot (histogram) of the dose at which each animal first responds is often roughly bell-shaped . The cumulative curve adds those animals and is the familiar sigmoid of probit analysis.
Worked frequency table. Ten mice have unique individual lethal thresholds (mg/kg): 12, 14, 15, 16, 18, 20, 22, 24, 28, 40 . Sum = 209 , so the mean is 20.9 mg/kg . The median of the ten values is the average of the 5th and 6th, (18 + 20) / 2 = 19 mg/kg .
- Dose bin (mg/kg) New deaths in bin (frequency) Cumulative deaths Cumulative %
- 10–14 2 2 20%
- 15–19 3 5 50%
- 20–24 3 8 80%
- 25–40 2 10 100%
Frequency peaks in the middle two bins ( 3 + 3 ). Cumulative percent is 20, 50, 80, 100 —the sigmoid. The LD50 sits where cumulative incidence is 50%, here in the 15–19 mg/kg bin, near the median of 19 , not at the 40 mg/kg outlier and not automatically at the histogram’s visual pile-up if the distribution is skewed. Confusing the frequency mode with the cumulative median is a high-yield error.
Threshold, linear no-threshold, and other nonlinear shapes
Threshold (nonlinear, a dose below which the adverse effect does not appear above background). For most noncancer apical effects—necrosis after a repairable insult, cholinesterase inhibition that must exhaust reserve, renal failure after tubular compensation is spent—homeostasis implies a region of no incremental adversity in the tested population. Risk assessment may still apply uncertainty factors below the PoD (Chapter 13). That arithmetic is not a claim that the biological threshold equals the NOAEL.
Linear no-threshold. In EPA 2005 cancer practice, agents with a mutagenic mode of action are assessed with default linear extrapolation: extra cancer risk is treated as proportional to dose at low dose , with no dose assigned zero incremental risk . The PoD (often a BMDL10 ) is connected to the origin; the slope of that line is the cancer slope factor in section 12.3. EPA does not force LNT on every carcinogen. If a well-supported nonlinear mode of action is accepted—for example cytotoxicity with regenerative proliferation as the driver of tumors—a threshold-style reference value may be derived instead. The examination tests whether you know the mutagenic-carcinogen default , not whether you can relitigate radiation epidemiology.
Nonlinear without a sharp threshold. Saturation of clearance, receptor occupancy approaching 100%, and glutathione depletion produce curves that steepen or flatten once a pathway saturates. That is still nonlinear. It is not automatically hormesis.
Hormesis and endocrine non-monotonicity
Hormesis is a J-shaped or inverted-U pattern: a low-dose change in the opposite direction from the high-dose toxic effect (low-dose growth stimulation, high-dose inhibition). It is a hypothesis to test with data, not a default for IRIS files or ICH M3 packages.
Non-monotonic dose–response (NMDR) is broader: the slope changes sign at least once. Endocrine-active agents (some receptor agonists and antagonists) are the teaching example, because receptor occupancy can stimulate at low occupancy and then desensitize, recruit different cofactors, or give way to ordinary cytotoxicity at high concentration. A reporter assay that peaks at 0.1 nM and returns toward baseline at 10 nM is NMDR. Killing the cells at 10 µM is high-dose toxicity, not proof of hormesis.
Design consequence: a study that only tests 100, 300, and 1000 mg/kg may miss a low-dose endocrine peak. That is a dose-placement problem, not a license to draw a U-shape through two noisy means.
Therapeutic index and the nutrient U-shape
Therapeutic index (TI) in classical pharmacology is TD50 / ED50 (sometimes LD50 / ED50). If the median toxic dose is 200 mg/kg and the median effective dose is 20 mg/kg , TI = 200 / 20 = 10 . A TI of 10 is more forgiving of pharmacokinetic variability than a TI of 2. TI uses population midpoints . It is not an RfD, not a CSF, and not a substitute for organ-specific NOAELs on a 90-day study.
Essential nutrients (vitamin A, copper, selenium, fluoride) produce a U-shaped health curve: deficiency disease at too little, toxicity at too much, with an adequate-intake trough in between. Treating selenium like a mutagenic carcinogen with LNT would “protect” people into deficiency cardiomyopathy. Treating vitamin A deficiency as proof that high-dose retinoids are harmless would miss teratogenicity . The U-shape is about homeostatic requirement plus excess toxicity , not a claim that every industrial chemical is a nutrient.
PBPK outputs as the x-axis
Administered mg/kg/day is a convenient external dose. When species differ in ventilation, protein binding, or metabolic clearance, the same external dose is not the same internal dose. PBPK models predict time courses of parent and metabolite in blood and tissues. Dose–response is then plotted against:
- Area under the curve (AUC) in venous blood or the target tissue, when cumulative exposure drives the effect
- Peak concentration (Cmax) when the peak drives the effect (some acute CNS effects; some teratogenic peaks)
Amount metabolized when a reactive metabolite is the toxicant (amount of NAPQI, not milligrams of acetaminophen in the bottle)
Using AUC as the metric can remove apparent species differences that were only clearance differences. Using Cmax when AUC is the true driver, or the reverse, is a misspecified dose metric. PBPK does not invent a threshold; it changes the x-axis on which threshold or linear models are fitted. Section 12.3 returns to PBPK as an interspecies tool for first-in-human dose.
Scenario
A 90-day rat study of a liver enzyme inducer shows a shallow continuous increase in relative liver weight (plateau not reached), no necrosis, and a quantal incidence of thyroid follicular hypertrophy of 0/10, 0/10, 2/10, 8/10 across four doses. The liver-weight curve is continuous and shallow; the thyroid finding is quantal and steep. An Ames-positive impurity in the same program is assessed for cancer with the mutagenic LNT default , not with the thyroid threshold story. A PBPK model that reports thyroid AUC of the parent , not gavage mg/kg, is the right x-axis if clearance differs between rat and human. A second file is selenium in feed: both the deficiency arm and the excess arm raise adverse findings—the U-shape—not an invitation to apply a cancer CSF to essential-nutrient deficiency.
Traps
Using LD50 as a chronic PoD or as an FIH dose.
Calling every laboratory sigmoid a biological threshold equal to the NOAEL.
Applying LNT to essential-nutrient deficiency, or applying a nutrient U-shape to a mutagenic industrial carcinogen without evidence.
Reading a frequency histogram’s peak as the ED50 without looking at the cumulative median.
Plotting administered dose when the toxicant is a metabolite AUC.
Treating hormesis as the required default for endocrine or cancer assessment.